Bypassing agents

Phase 3Small molecule

Roche

Bypassing agents is one of 65 small molecule programs targeting Von Willebrand disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Von Willebrand DiseaseActive, not recruiting

Hemophilia aActive, not recruiting

Von Willebrand Disease, Type 3Recruiting

Severe Hemophilia aActive, not recruiting

Von Willebrand DiseasePhase 3

Active, not recruiting

Hemophilia aPreclinical

Active, not recruiting

Von Willebrand Disease, Type 3Phase 3

Recruiting

Severe Hemophilia aPhase 3

Active, not recruiting

Competition

Competitive Landscape

93 competitors in Hemophilia a

#DrugCompanyPhaseTrials

Hemlibra

Roche

Phase 3

16 2

Recombinant Human Coagulation FVIII

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

2 3

Eptacog Alfa

Novo Nordisk

Phase 3

1 4

Qfitlia

GGenzyme, a Sanofi Company

Phase 3

1 5

Valoctocogene Roxaparvovec

BioMarin Pharmaceutical

Phase 3

3 6

Recombinant Factor VIII

Bayer

Phase 3

2 7

Translarna

PPTC Therapeutics

Phase 2

1 8

Marstacimab

Pfizer

Phase 3

1 9

Rfviia

Roche

Phase 3

1 10

PF-06741086

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Recruiting

Von Willebrand Disease, Type 3

NCT06998524

Clinical

Trials by Indication[1]

Severe Hemophilia a1 trial

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

Completed· Sanofi logo

Sanofi·Phase 3·NCT03417102·60 enrolled

Hemophilia A1 trial

A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment

Completed· Roche logo

Roche··NCT02476942·221 enrolled

Von Willebrand Disease, Type 31 trial

A Phase III, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Prophylaxis in Patients With Type 3 Von Willebrand Disease

Recruiting· Roche logo

Roche·Phase 3·NCT06998524·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Bypassing agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bypassing agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bypassing agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Bypassing agents

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Severe Hemophilia a1 trial

Hemophilia A1 trial

Von Willebrand Disease, Type 31 trial

References

Drug Info

Quick Facts

Related News